DANA-FARBER CANCER INSTITUTE

Remix Therapeutics will present Phase 1 clinical trial data for REM-422, a first-in-class oral small molecule MYB mRNA degrader, in patients with recurrent or metastatic adenoid cystic carcinoma at the AACR-NCI-EORTC International Conference.

Kernal Bio received up to $48 million from ARPA-H to advance its in vivo CAR-T cell therapy program KR-402, targeting multiple sclerosis and B-cell malignancies including acute lymphoblastic leukemia and large B-cell lymphoma.

Vaxiion Therapeutics completed Phase 1a dose escalation of VAX014, a first-in-class bacterial minicell-based oncolytic immunotherapy, demonstrating good tolerability and immune-mediated antitumor activity in 18 heavily pretreated solid tumor patients.

Larkspur Biosciences announced the discovery of LRK-4189, a first-in-class degrader targeting the lipid kinase PIP4K2C for treating microsatellite stable colorectal cancer.

Breast cancer patients in a remote weight-loss intervention program lost an average of 4.7% of their baseline body weight after one year, while control group participants gained 1% of their baseline weight.

Circle Pharma's CID-078, a first-in-class oral cyclin A/B RxL inhibitor, demonstrated robust anti-tumor activity in preclinical models, including chemotherapy-resistant small cell lung cancer xenografts.

Cue Biopharma has dosed the first patient with CUE-102 in a Phase 1b investigator-sponsored trial for recurrent glioblastoma multiforme at Dana-Farber Cancer Institute.

Researchers at Dana-Farber Cancer Institute have developed SWIFT-seq, a blood test that uses single-cell sequencing to profile circulating tumor cells and could replace painful bone marrow biopsies for multiple myeloma diagnosis and monitoring.

Dana-Farber Cancer Institute, Boston Children's Hospital, and Broad Clinical Labs have formed BrightSeq, a collaborative initiative to develop clinical molecular testing assays specifically for pediatric cancers.

A multi-institutional study found that 42% of ovarian cancer patients who achieved clinical remission after first-line therapy still harbored minimal residual disease (MRD) detectable through second-look laparoscopy.